Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | TK1 | P04183 | 3/20 | 0.62 |
| ▸ | TYMS | P04818 | 3/20 | 0.61 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19069606 | 1.00 | POLB (0.65) | POLBTK1TYMSRNASE1 | |
| SCHEMBL19069725 | 1.00 | POLB (0.65) | POLBTK1TYMSRNASE1 | |
| SCHEMBL16508397 | 1.00 | POLB (0.65) | POLBTK1TYMSRNASE1 | |
| SCHEMBL26189541 | 0.91 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL21504630 | 0.91 | POLB (0.63) | POLBTK1TYMS | |
| SCHEMBL16130860 | 0.91 | POLB (0.67) | POLBTK1TYMS | |
| SCHEMBL8529362 | 0.91 | POLB (0.67) | POLBTK1TYMS | |
| SCHEMBL29456897 | 0.91 | POLB (0.67) | POLBTK1TYMS | |
| SCHEMBL20987562 | 0.90 | POLB (0.66) | POLBTK1TYMS | |
| SCHEMBL20987563 | 0.90 | POLB (0.66) | POLBTK1TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | WAVE LIFE SCIENCES LTD. (SG) | 2019-06-25 | — | — | US | disclosed |
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | WAVE LIFE SCIENCES JAPAN, INC. (JP) | 2018-04-26 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111958-A1 | METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS | PNP, ADAR, NUDT1 | POLB 96/4885TK1 239/4885TYMS 559/4885 |
| US-10329318-B2 | Method for the synthesis of phosphorus atom modified nucleic acids | PNP, ADAR, NUDT1 | POLB 96/4885TK1 239/4885TYMS 559/4885 |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | POLB 327/4885TK1 148/4885TYMS 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.